Admilparant

Admilparant
Clinical data
Other names	BMS-986278
Identifiers
	IUPAC name (1S,3S)-3-[2-methyl-6-[1-methyl-5-[[methyl(propyl)carbamoyl]oxymethyl]triazol-4-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid;
CAS Number	2170126-74-4;
PubChem CID	132232205;
DrugBank	DB18011;
ChemSpider	115009679;
UNII	4UN9AOU6G8;
KEGG	D12657;
ChEMBL	ChEMBL5087506;
Chemical and physical data
Formula	C22H31N5O5
Molar mass	445.520 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN(C)C(=O)OCC1=C(N=NN1C)C2=NC(=C(C=C2)O[C@H]3CCC[C@@H](C3)C(=O)O)C;
	InChI InChI=InChI=1S/C22H31N5O5/c1-5-11-26(3)22(30)31-13-18-20(24-25-27(18)4)17-9-10-19(14(2)23-17)32-16-8-6-7-15(12-16)21(28)29/h9-10,15-16H,5-8,11-13H2,1-4H3,(H,28,29)/t15-,16-/m0/s1; Key:UEUNDURNLYLSNB-HOTGVXAUSA-N;

Admilparant is an investigational new drug being developed by Bristol-Myers Squibb for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is a first-in-class lysophosphatidic acid receptor 1 (LPA1) antagonist.^[1]^[2]

As of 2024, admilparant is in Phase III clinical trials for both IPF and PPF.^[2]^[3]

References

^ "Admilparant (BMS-986278): Idiopathic Pulmonary Fibrosis Likelihood of Approval". Pharmaceutical Technology. 25 December 2023. Retrieved 2024-11-23.
^ ^a ^b Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, et al. (October 2024). "Efficacy and Safety of Admilparant, an LPA1 Antagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial". American Journal of Respiratory and Critical Care Medicine. doi:10.1164/rccm.202405-0977OC. PMID 39393084.
^ Splete H (16 September 2024). "Admilparant Affects Biomarkers in Pulmonary Fibrosis". Medscape. Retrieved 2024-11-23.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.